Tonix Pharmaceuticals Holding Corp. (TNXP) insider have most recently took part in a trading activity. On Jun 26, 2017 Lederman Seth, CEO bought 5,000 shares having total worth of $22,000 at the price of $4.4 per share, following the transaction a total of 76,925 shares owned by Lederman Seth. Before this latest buy, Lederman Seth purchased TNXP at 2 other times during the past twelve months, for a total investment of $126,540 at an average of $2.33 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 4 times by insiders. an employee of the company was the buyer in 4 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) traded down 1.6% on Jun 23, 2017, hitting $4.3. 119,848 shares of the company’s stock traded hands. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $3.49 and a 52 week high of $52.6. The company’s market cap is $18 million.
Tonix Pharmaceuticals Holding Corp. (TNXP) last announced its earnings results on May 15, 2017. The company reported -1.27 earnings per share (EPS) for the quarter, higher than the consensus estimate of -1.36 by $0.09. During the same quarter in the previous year, the company posted -0.74 earnings per share.
|earnings per share||-1.27||-1.78||-0.29||-0.50||-0.74||-0.71||-0.72||-0.73||-0.71||-0.83|
Tonix Pharmaceuticals Holding Corp was incorporated on November 16, 2007 under the laws of the State of Nevada as Tamandare Explorations Inc. From inception through October 2011, the Company was involved in the acquisition, exploration and development of natural resource properties in the State of Nevada. On October 11, 2011, the Company changed the name to Tonix Pharmaceuticals Holding Corp. to reflect their new business. The Company is a specialty pharmaceutical company focused on developing pharmaceutical products for challenging disorders of the CNS. They search for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications they seek, but which may be approved for use in other indications.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018